1.
Am J Surg
; 134(4): 474-8, 1977 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-911030
RESUMEN
One hundred patients with advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck were treated with chemotherapy and BCG as adjuvant immunotherapy. The overall response rate was 35 per cent, and the median duration of response was seventeen weeks. BCG does not prolong duration of remission or survival time.